Term
| Different approaches of PD Tx |
|
Definition
I - increases in dopamine synthesis capacity
II - activation of post-synaptic receptors
III - inhibition of dopamine metabolism
IV - alteration of the interaction/balance with other neurotransmitters
V - dopamine releasers
VI - L-DOPA peripheral metabolism inhibitors |
|
|
Term
|
Definition
po.
Absorbed in the gut by the amino acid transport system.
Transported into the brain via large neutral amino acid (LNAA) carrier. |
|
|
Term
|
Definition
+95% of L-DOPA (p.o.) metabolized in the periphery to:
a) DA by AAAD
b) 3-O-methyl-L-DOPA by COMT |
|
|
Term
|
Definition
| aromatic amino acid decarboxylase |
|
|
Term
|
Definition
| catechol-o-methyltransferase |
|
|
Term
|
Definition
A peripheral L-DOPA decarboxylase inhibitor: reduces peripheral metabolism of L-DOPA.
*Carbidopa does not cross the BBB. |
|
|
Term
|
Definition
| L-DOPA + carbidopa (allows lower L-DOPA dosage == less side fx) |
|
|
Term
|
Definition
1. Nausea and vomiting (most common, but dev tolerance)
2. Hallucinations and psychosis
3. Hyperkinesias or dyskinesias (long-term)
4. Cardiovascular - orthostatic HTN
5. On-Off Effect (On: dyskinesia, off: akinesia) |
|
|
Term
|
Definition
| Deep brain stimulation (DBS) of the subthalamic nucleus (chronic depolarization --> inhibiting the firing) |
|
|
Term
|
Definition
D1,D5: increase adenylyl cyclase activity
D2,D3,D4: inhibit adenylyl cyclase activity |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
| A short-acting dopamine D1 and D2 receptor agonist; currently used for the management of sudden, unexpected and refractory levodopa-induced ‘off’ states in fluctuating Parkinson’s disease, either as intermittent rescue injections or continuous infusions. |
|
|
Term
|
Definition
| Nausea, hallucinations and psychotic behavior (frequent); also, orthostatic hypotension and fainting. |
|
|
Term
|
Definition
| Deprenyl. Selective MAO-B inhibitor. |
|
|
Term
|
Definition
| Selegiline. Selective MAO-B inhibitor. |
|
|
Term
|
Definition
| Azilect. Selective MAO-B inhibitor. |
|
|
Term
|
Definition
| Rasagiline. Selective MAO-B inhibitor. |
|
|
Term
|
Definition
| Muscarinic ACh antagonist |
|
|
Term
|
Definition
| Muscarinic ACh antagonist |
|
|
Term
|
Definition
H1 antagonist (antihistamine)
Significant central muscarinic antagonist |
|
|
Term
|
Definition
DA releaser.
Mild disease.
Excreted unchanged into the urine. (watch for kidney failure) |
|
|
Term
|
Definition
COMT inhibitor.
Inhibits COMT in the periphery only, thereby increasing the bioavailability of L-DOPA. |
|
|
